New drug combo tested to stop aggressive breast Cancer's return
NCT ID NCT03945721
Summary
This study is testing the safety of a drug called niraparib when given alongside standard radiation therapy after surgery. It involves 21 adults with triple-negative breast cancer who still have some cancer cells left after initial treatment. The goal is to see if this combination is safe and to find the right dose, with the hope it will help prevent the cancer from coming back in the chest area.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute/Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.